Unicycive Therapeutics (Nasdaq:UNCY) - 주가, 뉴스 및 분석

UNCY 주식 개요

유니사이시브 테라퓨틱스는 미국에서 다양한 질병에 대한 치료법을 개발하는 생명공학 회사입니다. 자세한 내용

UNCY 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	5/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 96.8% 에서 거래

수익은 매년 58.76% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $55M )

최근 3개월간 주가 변동성

Unicycive Therapeutics, Inc. 경쟁사

Burning Rock Biotech

NasdaqGM:BNR

US$57.4m

Vor Biopharma

NasdaqGS:VOR

US$54.3m

MAIA Biotechnology

NYSEAM:MAIA

US$52.1m

Dyadic International

NasdaqCM:DYAI

US$57.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Unicycive Therapeutics
과거 주가
현재 주가	US$0.53
52주 최고치	US$1.82
52주 최저치	US$0.20
베타	2.29
11개월 변경	27.71%
3개월 변경 사항	45.21%
1년 변경 사항	-12.38%
33년 변화	-81.85%
5년 변화	n/a
IPO 이후 변화	-90.94%

최근 뉴스 및 업데이트

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 21

Recent updates

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 21

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Sep 07

Unicycive Therapeutics GAAP EPS of -$0.24

Aug 16

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Jul 18

주주 수익률

	UNCY	US Biotechs	US 마켓
7D	15.2%	2.5%	2.2%
1Y	-12.4%	16.1%	31.6%

수익률 대 산업: UNCY 지난 1년 동안 16.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: UNCY 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is UNCY's price volatile compared to industry and market?
UNCY volatility
UNCY Average Weekly Movement	12.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: UNCY 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: UNCY 의 주간 변동성( 12% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2016	14	Shalabh Gupta	unicycive.com

유니사이시브 테라퓨틱스는 미국에서 다양한 질환에 대한 치료제를 개발하는 생명공학 회사입니다. 급성 신장 손상 치료제로 개발 중인 니코란딜의 전구 약물인 UNI 494와 만성 신장 질환 환자의 고인산혈증 치료제로 개발 중인 Renazorb(탄산옥실란타늄)를 신약 후보 물질로 보유하고 있습니다. 유니사이시브 테라퓨틱스는 실파 메디케어(Shilpa Medicare Ltd), 스파에라 파마(Sphaera Pharma Pte.

Unicycive Therapeutics, Inc. 기본 사항 요약

Unicycive Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
UNCY 기본 통계
시가총액	US$55.01m
수익(TTM)	-US$24.10m
수익(TTM)	n/a

0.0x

P/S 비율

-2.3x

P/E 비율

UNCY 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
UNCY 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$24.10m
수익	-US$24.10m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.23
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

UNCY 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

UNCY 주식 개요

보상

위험 분석

Unicycive Therapeutics, Inc. 경쟁사

NasdaqGM:BNR

US$57.4m

NasdaqGS:VOR

US$54.3m

NYSEAM:MAIA

US$52.1m

NasdaqCM:DYAI

US$57.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Price target increased by 8.2% to US$5.50

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Price target decreased by 12% to US$5.08

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

New major risk - Shareholder dilution

Recent updates

Price target increased by 8.2% to US$5.50

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Price target decreased by 12% to US$5.08

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

New major risk - Shareholder dilution

New major risk - Market cap size

Unicycive Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (Olc) At the National Kidney Foundation Spring Clinical Meeting

New major risk - Financial position

Unicycive Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Price target increased by 15% to US$5.30

Forecast to breakeven in 2026

Consensus EPS estimates fall by 71%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Unicycive Therapeutics, Inc. announced that it has received $50 million in funding

Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding

Consensus revenue estimates decrease by 11%

New minor risk - Profitability

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate

Unicycive Therapeutics Receives Non-Compliance Notices from Nasdaq

Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors

New minor risk - Profitability

Consensus EPS estimates upgraded to US$1.17 loss

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

New major risk - Shareholder dilution

No longer forecast to breakeven

Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program

Unicycive Therapeutics Receives Written Notification from Nasdaq Regarding Minimum Market Value Requirement Under Nasdaq Listing Rule 5550(b)(2)

Unicycive Therapeutics, Inc. announced delayed 10-Q filing

Price target decreased by 21% to US$7.40

Consensus revenue estimates increase by 33%

Forecast to breakeven in 2025

Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Unicycive Therapeutics Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1

Unicycive Therapeutics, Inc. Reports Key Findings of Uni-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for Renazorb™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (Ckd) Patients on Dialysis

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Unicycive Therapeutics GAAP EPS of -$0.24

Unicycive Therapeutics, Inc. Receives Written Notice from the Nasdaq Stock Market, LLC

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Unicycive Therapeutics, Inc. Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Unicycive Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Unicycive Therapeutics, Inc. Receives Confirmatory Guidance on Renazorb Regulatory Pathway

Unicycive Therapeutics, Inc. has completed an IPO in the amount of $25 million.

주주 수익률

가격 변동성

회사 소개

Unicycive Therapeutics, Inc. 기본 사항 요약

0.0x

-2.3x

수익 및 수익